Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY


Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in quality of life, many children and adults with HMs still die from these disorders or experience disabling complications. Therefore, improvement of health care of HMs is an unmet medical need. Thus, it is important to define and align standard and efficient sets of HMs outcomes to measure and evaluate HM data for clinical decisions, long term risk/benefit profile, reimbursement, value analysis, and clinical trials design. Improving outcome measures and endpoint definitions by taking into account “real-life” data and differences in cross-national healthcare practice will undoubtedly result in an optimized, sustainable and effective treatment delivery, as well as in desirable and innovative accelerated pathways for novel drug availability. All these challenges will be addressed within a pan-EU perspective by HARMONY (Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY), a comprehensive public-private European consortium of excellence. HARMONY consortium is made up of 51 partners: 44 participants from 10 European countries and 7 pharmaceutical companies from the EFPIA. HARMONY aims to assemble, assess, connect, and analyze heterogeneous HM patient derived Big Data sets to define sets of outcome indicators that can be used for decision-making by key healthcare stakeholders. The consortium will orchestrate leading experts and working cooperative groups in HMs, European study alliances, pharmaceutical market leaders, patient advocacy groups, HTA and regulatory agencies, to: (i) optimize Europe-wide data collection and create a high-quality HM data repository for further explorative studies; (ii) establish a clinical data-sharing platform that empowers clinicians, patients and policy stakeholders to improve decision-making procedures and identify appropriate treatments to patients with HMs (iii) foster the design of innovative clinical and pre-clinical studies; (iv) define meaningful and harmonized clinical endpoints and outcomes in HMs in order to facilitate clinical decision-making; (v) identify specific biomarkers, which better define outcome parameters (vi) provide novel resources and algorithms to more rapidly advance innovative concepts of patient management in HMs; (vii) involve the patient perspective; (viii) provide a framework for legal, ethical and governance issues. Moreover, the consortium will integrate molecular markers to improve patient outcomes and personalized health management processes.   Regarding governance, HARMONY has a multi-level organizational structure, which includes representatives from all stakeholders, and which, ensures efficient and effective management, decision-making, and control of work package (WP) activities. This will be accomplished by creating well-defined management and decision-making structures with clear accountabilities and decision rules. The Consortium Management Bodies will be the Executive Committee, the Steering Committee, and the General Assembly. The management of Big Data is one of the key-features in the consortium. Therefore a Data Quality Supervision Committee will define the quality criteria for “valid records” and perform the review of the quality of the patients’ data provided by different sources (beneficiaries, Associated Members and Co-operative Working Groups).  HARMONY is covering seven HMs (multiple myeloma, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, myelodysplastic syndromes and pediatric HMs) structured in eight WPs, including: i) the most important key opinion leaders in each disease; ii) several European institutions involved in the study of HMs; iii) the EFPIA lead companies in HMs; iv) institutions experienced in studying “o

Project details

Unibo Team Leader: Giovanni Martinelli

Unibo involved Department/s:
Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale
Dipartimento di Fisica e Astronomia "Augusto Righi"

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León(Spain)

Other Participants:
University Of Cambridge (United Kingdom)
MediSapiens Oy (Finland)
Bayer Ag (Germany)
Bundesinstitut für Arzneimittel und Medizinprodukte (Germany)
Università  degli Studi di ROMA Tor Vergata (Italy)
Erasmus Universitair Medisch Centrum Rotterdam (Netherlands)
Josep Carreras Leukaemia Research Institute (IJC)-José Carreras International Foundation (Spain)
Celgene Management Sarl (Switzerland)
Eortc Aisbl/Ivzw (Belgium)
Ludwig-Maximilians-Universitat Munchen (Lmu) (Germany)
Gpoh-Gesellschaft Fur Padiatrische Onkologie Und Hamatologie Ggmh (Germany)
Masarykova Univerzita (Czech Republic)
The Lymphoma Scientific Association (France)
Assistance Publique - Hopitaux De Paris (France)
Mll - Munchner Leukamielabor Gmbh (Germany)
Università degli Studi di TORINO (Italy)
Ospedale Pediatrico Bambino Gesu' (Italy)
Synapse Research Management Partners Sl (Spain)
University Of York (United Kingdom)
Groupe Francophone des Myélodysplasies (France)
A.Menarini - Ind. Farm.Riunite - S.R.L. (Italy)
Janssen Pharmaceutica Nv (Belgium)
Group for Research on Adult Acute Lymphoblastic Leukemia-GRAALL (France)
Heinrich-Heine-Universität Düsseldorf (Germany)
Fondazione Italiana Sindromi Mielodisplastiche-FISM onlus (Italy)
European Hematology Association (Netherlands)
Ebmt European Group For Blood And Marrow Transplantation (Netherlands)
Stichting Vu (Netherlands)
Agencia Española del Medicamento y Productos Sanitarios (Spain)
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Spain)
Novartis Pharma Ag (Switzerland)
National Institute For Health And Care Excellence-Nice (United Kingdom)
Medizinische Universitat Wien (Austria)
European Alliance for Personalised Medicine (Belgium)
Leukanet e.V. (Germany)
European Research Initiative on CLL e.V. (Germany)
University of Navarra (Spain)
Universitaet Ulm (Germany)
Johann Wolfgang Goethe - Universitaet Frankfurt Am Main (Germany)
ALMA MATER STUDIORUM - Università di Bologna (Italy)
Fondacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana (Hulafe) (Spain)
Amgen Limited (United Kingdom)
Takeda Cambridge Ltd. (United Kingdom)
European LeukemiaNet Foundation-ELN-FOUNDATION (Germany)
GMV Soluciones Globales Internet S.A.U. (Spain)
Barts Cancer Institute QMUL (United Kingdom)
Genome Research Limited (United Kingdom)
Newcastle University (United Kingdom)
Vib Nucleomics Core (Belgium)
Helsingin Yliopisto (Finland)

Total Eu Contribution: Euro (EUR) 20.200.000,00
Project Duration in months: 60
Start Date: 01/01/2017
End Date: 31/12/2021

Cordis webpage
Project website

Good health and well-being This project contributes to the achievement of the Sustainable Development Goals of the UN 2030 Agenda.

UE flag This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 116026